| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | LST1 |
| Uniprot No | O00453 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-66aa |
| 氨基酸序列 | MLSRNDVKRLERSWAQGSSEQELHYASLQRLPVPSSEGPDLRGRDKRGTKEDPRADYACIAENKPT |
| 预测分子量 | 11.5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于LST1重组蛋白的示例性参考文献(注：以下为模拟文献示例，实际文献需通过学术数据库查询)：
---
1. **文献名称**: *"Characterization of LST1 Recombinant Protein in Immune Regulation"*
**作者**: Müller et al. (2005)
**摘要**: 研究通过基因重组技术表达了LST1蛋白，发现其参与MHC III类分子区域的免疫调节功能，并在体外实验中抑制T细胞活化。
2. **文献名称**: *"Structural Insights into LST1 Protein and Its Interaction with TLR4"*
**作者**: Zhang et al. (2012)
**摘要**: 解析了LST1重组蛋白的晶体结构，揭示了其与Toll样受体4(TLR4)的结合机制，为炎症反应调控提供了分子基础。
3. **文献名称**: *"LST1 Recombinant Protein Attenuates Autoimmune Encephalomyelitis in Mice"*
**作者**: Rossi et al. (2018)
**摘要**: 在小鼠多发性硬化模型中，LST1重组蛋白通过调节巨噬细胞极化减轻神经炎症，提示其治疗自身免疫疾病的潜力。
4. **文献名称**: *"High-Yield Production of LST1 in E. coli for Therapeutic Applications"*
**作者**: Kim & Park (2020)
**摘要**: 开发了基于大肠杆菌的高效LST1重组蛋白表达系统，并验证其稳定性与生物活性，为规模化生产奠定基础。
---
建议通过PubMed、Web of Science或Google Scholar检索关键词“LST1 recombinant protein”获取真实文献。
**Background of LST1 Recombinant Protein**
LST1 (Leukocyte-Specific Transcript 1) is a protein encoded by the *LST1* gene located within the major histocompatibility complex (MHC) class III region on human chromosome 6. Initially identified as a leukocyte-specific transcript, LST1 is expressed predominantly in immune cells, including monocytes, macrophages, and dendritic cells, suggesting a role in immune regulation. The gene produces multiple splice variants, yielding protein isoforms with diverse structures and potential functions, such as membrane-bound or soluble forms. LST1 has been implicated in modulating immune responses, including inflammation, cell adhesion, and apoptosis, though its precise molecular mechanisms remain under investigation.
Recombinant LST1 protein is engineered through molecular cloning techniques, often expressed in heterologous systems like *E. coli* or mammalian cell lines (e.g., HEK293) to ensure proper folding and post-translational modifications. The recombinant form enables controlled studies of LST1's biological activities, such as its interaction with immune receptors (e.g., SHP-1. CD94) or its influence on signaling pathways like NF-κB. Researchers utilize LST1 recombinant protein to explore its role in autoimmune diseases, infectious responses, and cancer, where dysregulated LST1 expression has been observed.
Structural studies of recombinant LST1 highlight conserved domains critical for immune functions, including a transmembrane region and cytoplasmic signaling motifs. Its application extends to developing therapeutic strategies, such as targeting LST1 pathways to modulate aberrant immune activation. Despite progress, challenges like understanding isoform-specific functions and optimizing recombinant production for clinical use remain active areas of research. Overall, LST1 recombinant protein serves as a vital tool for deciphering immune regulation and advancing immunotherapeutic innovations.
×
